SCHEMBL474415

SCHEMBL474415

CC(=O)[C@@]1(n2cnc3c(N)ncnc32)O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]1O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RY1 P47900 5/20 0.56
P2RY2 P41231 3/20 0.56
SRC P12931 2/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
DNPH1 O43598 1/20 0.56
PRKAB2 O43741 1/20 0.56
TRPM2 O94759 1/20 0.56
LDHA P00338 1/20 0.56
ADRB2 P07550 1/20 0.56
FBP1 P09467 1/20 0.56
ADORA1 P30542 1/20 0.56
PRKAG1 P54619 1/20 0.56
PRKAA2 P54646 1/20 0.56
PDE4D Q08499 1/20 0.56
KCNH2 Q12809 1/20 0.56
PRKAA1 Q13131 1/20 0.56
PDE3A Q14432 1/20 0.56
TAS1R3 Q7RTX0 1/20 0.56
TAS1R1 Q7RTX1 1/20 0.56
P2RY11 Q96G91 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28769844 0.91 P2RY1 (0.57) P2RY1P2RY2SRCSMN1; SMN2DNPH1
SCHEMBL9394425 0.88 P2RY1 (0.51) P2RY1P2RY2SRCSMN1; SMN2DNPH1
Phosphoric Acid SCHEMBL474409 0.87 ADORA1 (0.48) P2RY1P2RY2SRCSMN1; SMN2DNPH1
SCHEMBL30474605 0.85 P2RY1 (0.49) P2RY1P2RY2SRCSMN1; SMN2DNPH1
SCHEMBL2791981 0.85 P2RY1 (0.59) P2RY1P2RY2SRCSMN1; SMN2DNPH1
SCHEMBL30195073 0.85 P2RY1 (0.59) P2RY1P2RY2SRCSMN1; SMN2DNPH1
SCHEMBL16108838 0.85 P2RY1 (0.59) P2RY1P2RY2SRCSMN1; SMN2DNPH1
SCHEMBL219553 0.85 ADORA3 (0.49) SMN1; SMN2ADORA1
SCHEMBL16700549 0.85 P2RY1 (0.58) P2RY1P2RY2SRCSMN1; SMN2DNPH1
SCHEMBL10824472 0.84 P2RY1 (0.60) P2RY1P2RY2SRCSMN1; SMN2DNPH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250243168-A1 ACETYL-COA SYNTHETASE 2 (ACSS2) INHIBITORS AND METHODS USING SAME THE WISTAR INST (US) 2025-07-31 US disclosed
US-12281084-B2 Acetyl-CoA synthetase 2 (ACSS2) inhibitors and methods using same THE WISTAR INSTITUTE (US) 2025-04-22 US disclosed
US-20220281826-A1 ACETYL-COA SYNTHETASE 2 (ACSS2) INHIBITORS AND METHODS USING SAME THE WISTAR INSTITUTE 2022-09-08 US disclosed
CN-114466840-A acetyl-CoA synthetase 2(ACSS2) inhibitors and methods of use thereof 威斯达研究所 2022-05-10 CN disclosed
EP-3983391-A1 ACETYL-COA SYNTHETASE 2 (ACSS2) INHIBITORS AND METHODS USING SAME The Wistar Institute (US) 2022-04-20 EP disclosed
WO-2020252407-A1 ACETYL-COA SYNTHETASE 2 (ACSS2) INHIBITORS AND METHODS USING SAME THE WISTAR INSTITUTE (US) 2020-12-17 WO disclosed
US-8518635-B2 Regulation of protein activity by reversible acetylation THE J. DAVID GLADSTONE INSTITUTES (US) 2013-08-27 US disclosed
EP-2029731-B1 REGULATION OF PROTEIN ACTIVITY BY REVERSIBLE ACETYLATION DAVID GLADSTONE INST (US) 2012-02-01 EP disclosed
CN-101490250-A Regulation of protein activity by reversible acetylation DAVID GLADSTONE INST (US) 2009-07-22 CN disclosed
US-20090061015-A1 Regulation of Protein Activity By Reversible Acetylation THE J. DAVID GLADSTONE INSTITUTES (US) 2009-03-05 US disclosed
EP-2029731-A2 REGULATION OF PROTEIN ACTIVITY BY REVERSIBLE ACETYLATION The J. David Gladstone Institutes (US) 2009-03-04 EP disclosed
WO-2007149270-A9 REGULATION OF PROTEIN ACTIVITY BY REVERSIBLE ACETYLATION DAVID GLADSTONE INST (US) 2008-03-06 WO disclosed
WO-2007149270-A2 REGULATION OF PROTEIN ACTIVITY BY REVERSIBLE ACETYLATION THE J. DAVID GLADSTONE INSTITUTES (US) 2007-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12281084-B2 Acetyl-CoA synthetase 2 (ACSS2) inhibitors and methods using same ACSS2, ACACB, ACACA P2RY1 4495/4885P2RY2 3879/4885SRC 2755/4885
US-20220281826-A1 ACETYL-COA SYNTHETASE 2 (ACSS2) INHIBITORS AND METHODS USING SAME ACSS2, ACACB, ACACA P2RY1 4495/4885P2RY2 3879/4885SRC 2755/4885
US-20250243168-A1 ACETYL-COA SYNTHETASE 2 (ACSS2) INHIBITORS AND METHODS USING SAME ACSS2, ACACB, ACACA P2RY1 4495/4885P2RY2 3879/4885SRC 2755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.